Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
G7 Explores AI Access Deal With U.S. Amid Anthropic Restrictions 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
Trump Says Anthropic No Longer Seen as National Security Threat 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
Google Gemini Co-Lead Noam Shazeer Leaves for OpenAI Amid AI Talent Race 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
WuXi AppTec Co. (SS:603259) announced that its board has approved the distribution of a 2025 interim dividend, highlighting strong financial performance and confidence in future growth. The pharmaceutical and life sciences company will pay 3.50 yuan per 10 shares, with a total payout of 1 billion yuan scheduled for September 26, 2025.
Following the announcement, WuXi AppTec shares saw a positive market reaction. The company’s Hong Kong-listed stock rose 2.5% to HK$113.1, while its Shanghai-listed shares increased 0.7% to 109.55 yuan. Investors welcomed the dividend decision, viewing it as a sign of the company’s stable operations and optimistic outlook.
In its statement, WuXi AppTec emphasized that the payout reflects the board’s assessment of the firm’s operating results and overall financial strength. The move underscores the company’s strategy of rewarding shareholders while continuing to invest in long-term development across its global operations.
WuXi AppTec is a leading global provider of R&D and manufacturing services for the pharmaceutical, biotechnology, and medical device industries. With strong revenue streams and expanding international partnerships, the company remains positioned to benefit from rising demand in healthcare innovation.
The 2025 mid-year dividend marks another milestone for the company, reinforcing its track record of consistent shareholder returns. Market analysts noted that such decisions not only boost investor confidence but also support the stock’s long-term value in both Shanghai and Hong Kong markets.
By aligning its dividend strategy with solid financial results and a positive business outlook, WuXi AppTec continues to strengthen its reputation as a reliable growth-driven enterprise in China’s healthcare sector.
